Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yunnan Biovalley Pharmaceutical CoBJSE:920266 74 Return-on-Tangible-Equity is 0.14% as of Jun. 2026, which is 98% below its 10-year median of 8.79. GuruFocus rates BJSE:920266 with a GF Score™ of 74/100 and a GF Value™ of ¥7.81 (Fairly Valued). The stock has 3 warning signs investors should review. Among 895 Drug Manufacturers companies, Yunnan Biovalley Pharmaceutical Co ranks worse than 75.53% on this metric.
The historical rank and industry rank for Yunnan Biovalley Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
BJSE:920266'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -8.56 Med: 8.79 Max: 23.27
Current: -3.48
During the past 13 years, Yunnan Biovalley Pharmaceutical Co's highest Return-on-Tangible-Equity was 23.27%. The lowest was -8.56%. And the median was 8.79%.
BJSE:920266's Return-on-Tangible-Equity is ranked worse than 75.53% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.85
vs BJSE:920266: -3.48
Yunnan Biovalley Pharmaceutical Co (BJSE:920266) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Yunnan Biovalley Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Yunnan Biovalley Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yunnan Biovalley Pharmaceutical Co Return-on-Tangible-Equity Chart
BJSE:920266 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Yunnan Biovalley Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yunnan Biovalley Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yunnan Biovalley Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Yunnan Biovalley Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.14% mean?
Yunnan Biovalley Pharmaceutical Co (BJSE:920266) has a Return-on-Tangible-Equity of 0.14% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors. This is 98% below median its historical median of 8.79. According to the industry distribution chart, Yunnan Biovalley Pharmaceutical Co ranks #676 out of 895 companies in the Drug Manufacturers industry, placing it in the top 75.5%.
Is Yunnan Biovalley Pharmaceutical Co's Return-on-Tangible-Equity too high?
Yunnan Biovalley Pharmaceutical Co's current Return-on-Tangible-Equity of 0.14% is 98% below median its 10-year median of 8.79. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.85. Yunnan Biovalley Pharmaceutical Co's value of 0.14% is 98.2% below this industry median. Based on the distribution chart, Yunnan Biovalley Pharmaceutical Co ranks #676 out of 895 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Yunnan Biovalley Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Yunnan Biovalley Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Yunnan Biovalley Pharmaceutical Co ranks #676 out of 895 companies for Return-on-Tangible-Equity. This places Yunnan Biovalley Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.85. Yunnan Biovalley Pharmaceutical Co's value of 0.14% is 98.2% below this benchmark. While the company's 10-year median is 8.79 vs. the industry median of 7.85, Yunnan Biovalley Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.85, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yunnan Biovalley Pharmaceutical Co's current Return-on-Tangible-Equity of 0.14% is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yunnan Biovalley Pharmaceutical Co's current Return-on-Tangible-Equity is 0.14%, which is 98% below median its own 10-year median of 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yunnan Biovalley Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co (BJSE:920266) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.81, compared to a current price of ¥7.35 — trading 5.9% below its estimated fair value. The current Return-on-Tangible-Equity is 0.14%, which is 98% below median its 10-year median of 8.79 and 98.2% below the Drug Manufacturers industry median of 7.85. Yunnan Biovalley Pharmaceutical Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Yunnan Biovalley Pharmaceutical Co (BJSE:920266), the current Return-on-Tangible-Equity is 0.14% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yunnan Biovalley Pharmaceutical Co (BJSE:920266) Overvalued in 2026?
Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.35 is trading 5.9% below its estimated GF Value™ of ¥7.81.
GuruFocus considers Yunnan Biovalley Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920266:
Return-on-Tangible-Equity: 0.14% (98% below median its 10-year median of 8.79)
GF Value™: ¥7.81 vs. price of ¥7.35 (5.9% below fair value)
Industry Position: 98.2% below the Drug Manufacturers median (#676 of 895)
No single metric tells the full story. See the BJSE:920266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yunnan Biovalley Pharmaceutical Co Ltd engages in research and development, production, and marketing of pharmaceuticals and health care based on herbal medicines. The products on the market include breviscapine injection, breviscapine Shengmai capsules, breviscapine tablets, breviscapine dripping pills, Erigeron Capsules, Erigeron Soft Capsules.
74GF Score
Get the complete analysis for BJSE:920266
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920266 has been successfully added to your 
